Unique panel of biomarkers identified for oesophageal cancer
Filed with ASX · · 10 pages · English
Proteomics International Laboratories Ltd. on 6ix
Earlier from Proteomics International Laboratories
- December 2021 Quarterly Activities Report and Appendix 4C
- Proteomics secures major pharmacokinetic testing contract
- Proteomics receives $1.2 million in R&D tax incentive
- PromarkerD distribution network expands to Britain
- PromarkerD outperforms standard of care tests for DKD
Later from Proteomics International Laboratories
- PromarkerD completes pre-assessment for Medicare rebate
- New Clinical Advisory Board for PromarkerD global rollout
- March 2022 Quarterly Activities Report and Appendix 4C
- Proteomics awarded $400,000 funding to support manufacturing
- PromarkerD manufacturing tech-transfer completed
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories